Ebola: Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP | Rebecca Coulborn

Описание к видео Ebola: Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP | Rebecca Coulborn

The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease (EVD) outbreaks. Using a retrospective cohort analysis of patients with confirmed EVD admitted to
Ebola health facilities in the Democratic Republic of the Congo between July 27,
2018, and April 27, 2020, Epicentre carried out univariate and multivariate analyses to
assess case fatality risk (CFR) and cycle threshold for nucleoprotein according to
vaccination status, EVD-specific treatments, and other risk factors.Among EVD-confirmed patients, vaccination reduced the risk of dying from EVD by more than half compared to being unvaccinated, even after adjusting for risk factors.

Комментарии

Информация по комментариям в разработке

Похожие видео